Artisan Partners Limited Partnership cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 14.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,075,127 shares of the company’s stock after selling 525,043 shares during the period. Artisan Partners Limited Partnership owned 0.11% of Johnson & Johnson worth $399,797,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. grew its stake in Johnson & Johnson by 1.5% in the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after purchasing an additional 3,023,110 shares during the period. BlackRock Inc. grew its stake in Johnson & Johnson by 2.6% in the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after purchasing an additional 4,332,612 shares during the period. Bank of New York Mellon Corp grew its stake in Johnson & Johnson by 0.4% in the third quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock worth $4,757,593,000 after purchasing an additional 130,437 shares during the period. FMR LLC grew its stake in Johnson & Johnson by 5.9% in the second quarter. FMR LLC now owns 27,237,648 shares of the company’s stock worth $3,603,268,000 after purchasing an additional 1,509,745 shares during the period. Finally, Capital World Investors grew its stake in Johnson & Johnson by 4.1% in the second quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock worth $3,507,009,000 after purchasing an additional 1,050,000 shares during the period. 67.23% of the stock is currently owned by hedge funds and other institutional investors.
JNJ stock traded down $3.59 during trading on Monday, reaching $124.56. The stock had a trading volume of 8,916,862 shares, compared to its average volume of 8,205,068. Johnson & Johnson has a 52 week low of $120.95 and a 52 week high of $148.32. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.12 and a current ratio of 1.41. The company has a market cap of $343,813.88, a price-to-earnings ratio of 17.06, a P/E/G ratio of 2.04 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.02. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The company had revenue of $20.20 billion for the quarter, compared to the consensus estimate of $20.08 billion. During the same quarter in the prior year, the company earned $1.58 earnings per share. Johnson & Johnson’s revenue was up 11.5% on a year-over-year basis. equities analysts predict that Johnson & Johnson will post 8.11 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th were given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.70%. The ex-dividend date of this dividend was Monday, February 26th. Johnson & Johnson’s payout ratio is 46.03%.
Several equities research analysts have commented on JNJ shares. Vetr downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating and set a $124.55 target price on the stock. in a report on Monday, March 26th. Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the stock a “hold” rating in a report on Monday, January 22nd. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Wells Fargo reissued an “outperform” rating and issued a $160.00 target price (up from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Finally, Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $144.43.
In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the sale, the vice president now owns 357,906 shares in the company, valued at $46,477,673.16. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.22% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.